1. Home
  2. ZLAB vs IMNM Comparison

ZLAB vs IMNM Comparison

Compare ZLAB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

HOLD

Current Price

$18.57

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.58

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZLAB
IMNM
Founded
2013
2006
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.6B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
ZLAB
IMNM
Price
$18.57
$22.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$49.60
$32.80
AVG Volume (30 Days)
640.0K
910.6K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
38.46
51.40
EPS
N/A
N/A
Revenue
$460,156,000.00
$6,941,000.00
Revenue This Year
$9.75
N/A
Revenue Next Year
$26.03
$1,127.34
P/E Ratio
N/A
N/A
Revenue Growth
15.33
N/A
52 Week Low
$15.96
$7.96
52 Week High
$44.34
$27.65

Technical Indicators

Market Signals
Indicator
ZLAB
IMNM
Relative Strength Index (RSI) 41.21 52.61
Support Level $16.88 $19.28
Resistance Level $19.64 $23.24
Average True Range (ATR) 0.87 1.21
MACD -0.14 0.05
Stochastic Oscillator 22.67 68.72

Price Performance

Historical Comparison
ZLAB
IMNM

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: